DalsnaFinance

Nanobiotix $NBTX

Health Care

France
Create a scorecard
$25.10
-0.65 (-2.52%)
As of Oct 5, 2026, 5:14 PM EDT
Price history
Loading chart…

Nanobiotix (NBTX) is trading down at $25.10 (-2.52%), as of the latest quote. It operates in the Health Care sector.

IPO: December 11, 2020 · $13.50 offering · NASDAQ · View IPO details →

Nanobiotix revenue & net income history (FY2018–FY2025)

RevenueNet income
€36.2M−€16.0M−€68.1MFY2018 revenue: €3.48MFY2018 net income: −€30.3M'18FY2019 revenue: €2.54MFY2019 net income: −€50.9M'19FY2020 revenue: €2.51MFY2020 net income: −€33.6M'20FY2021 revenue: €2.65MFY2021 net income: −€47.1M'21FY2022 revenue: €4.78MFY2022 net income: −€57.0M'22FY2023 revenue: €36.2MFY2023 net income: −€39.7M'23FY2024 revenue: −€7.19MFY2024 net income: −€68.1M'24FY2025 revenue: €32.6MFY2025 net income: −€24.0M'25
Nanobiotix annual financial statements
FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue€3.48M€2.54M€2.51M€2.65M€4.78M€36.2M−€7.19M€32.6M
Growth (year over year)—−27.0%−1.1%+5.4%+80.4%+658.1%−119.9%—
Operating income−€30.1M−€46.8M−€36.4M−€52.6M−€46.7M−€26.8M−€68.4M−€10.8M
Operating margin−864.2%−1841.0%−1450.2%−1986.4%−977.8%−74.0%—−33.2%
Net income−€30.3M−€50.9M−€33.6M−€47.1M−€57.0M−€39.7M−€68.1M−€24.0M
Net margin−872.2%−2003.7%−1337.2%−1778.0%−1194.3%−109.6%—−73.5%
EPS (diluted)−€1.55−€2.35−€1.38−€1.35−€1.64−€1.08−€1.44−€0.50
Balance sheet
Cash and equivalents€36.2M€35.1M€119.2M€83.9M€41.4M€75.3M€49.7M€52.8M
Total assets€51.6M€56.2M€134.0M€101.8M€59.8M€93.9M€67.4M€67.8M
Total liabilities€37.3M€58.1M€63.6M€75.0M€86.8M€95.7M€133.1M€152.2M
Shareholders' equity€14.2M−€1.91M€70.5M€26.8M−€27.0M−€1.84M−€65.7M−€84.5M
Cash flow
Operating cash flow−€26.0M−€41.2M−€27.5M−€29.9M−€37.1M−€12.5M−€19.6M−€33.4M
Capital expenditure€416.0K€1.09M€96.0K€228.0K€92.0K€328.0K€846.0K€538.0K
Free cash flow−€26.4M−€42.3M−€27.6M−€30.1M−€37.2M−€12.8M−€20.4M−€34.0M

From Nanobiotix's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Euro (EUR), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →

About Nanobiotix

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

Source: Wikipedia — Nanobiotix

Headquarters
Paris, France From SEC filings, Oct 2026

Recent News

No recent news mentioning Nanobiotix in our feed yet.

More Health Care stocks

Browse all companies →